Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety And Efficacy Data With Picoplatin In Metastatic Prostate Cancer Patients
Feb 19th 2008Drug InformationClinical Trials
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that it is presenting safety and efficacy data in prostate cancer patients from its Phase 1 study of picoplatin, the Company’s lead product candidate, at the 2008 Genitourinary (GU) Cancers Symposium, a meeting of the American Society of Clinical Oncology (ASCO) that is being held in San Francisco.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
